Product Description
The orally active hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitor enarodustat (ENAROY¨, Japan Tobacco) is being developed as an alternative to injectable erythropoietin stimulating agents such as epoetin and darbepoetin for the treatment of anaemia associated with chronic kidney disease (CKD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33320297/)
Mechanisms of Action: HIF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan | Korea
Approved Indications: None
Known Adverse Events: None
Company: Japan Tobacco
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Anemia
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2071210099 | P1 |
Completed |
Kidney Diseases|Anemia |
2022-06-30 |
|
CTR20202454 | P1 |
Not yet recruiting |
Anemia |
None |
|
CTR20232186 | P3 |
Not yet recruiting |
Anemia |
None |
|
CTR20202445 | P3 |
Recruiting |
Anemia |
None |